EvaluateMedTech2015-2020年全球医疗器械市场预测分析

EvaluateMedTech®WorldPreview2015,Outlookto20204thEdition–October2015WelcometotheEvaluateMedTech®WorldPreview2015,Outlookto2020OurfourthannualEvaluateMedTech®WorldPreviewbringstogethermanyofouranalysestoprovideatoplevelinsightintotheexpectedperformanceofthemedtechindustrybetweennowand2020.BasedonEvaluateMedTech®’scoverageoftheworld’sleadingmedicaldeviceanddiagnosticcompanies,theWorldPreviewhighlightstrendsinmedtechincluding:consensussalesforecastsofleadingindustryanalystsbydeviceareato2020;thetop20companiesin2020;R&Dspendcurrentandfuture;FDAapprovals;M&A;venturefinancing;IPOs;andenterprisevalue.Complimentarycopiesofthefullreportcanbedownloadedat:®WorldPreview20152Copyright©2015EvaluateLtd.Allrightsreserved.EvaluateMedTech®providestrustedglobalmedtechmarketintelligenceandconsensusforecastsdeliveredthroughasingleintegratedandstandardisedplatform,thateasilyintegrateswithyourownanalyticalmodels.Itallowsmedtechcompanies,financialinstitutions,consultancies,serviceprovidersandotherstoefficientlytrack,benchmarkandforecastthesectorsomoretimecanbespentexamininginsightsandmakingeffectivedecisionstooptimiseperformance.TofindoutmoreaboutthisreportandEvaluate’srangeofservicesforthelifesciencesectorpleasecontactus:NorthAmerica:AlanRaiderTel:[phone]/Email:[e-mail]:WillHauTel:[phone]/Email:[e-mail]:HiroshiYamazakiTel:[phone]/Email:[e-mail]:ChristineLindgrenTel:[phone]/Email:[e-mail]tyrightsinthisreportremainthatofEvaluateLtdand/oritsrespectivethirdpartylicensors.Whilstallreasonablestepshavebeentakentoensurethatthedatapresentedareaccurate,EvaluateLtdcannotacceptresponsibilityforerrorsoromissions.NeitherdoesEvaluateLtdwarranttheaccuracy,merchantabilityorfitnessforaparticularpurposeofthedata.Nothinginthereportsshallconstituteinvestment,financialorlegaladviceandthecontentsofthereportsareprovidedforinformationpurposesonly.Thedataisnotintendedtoamounttoadviceandshouldnotbeusedasadeterminingfactorinanyinvestmentdecision.Thisreportmaynotbelent,resold,hiredoutorotherwisedisposedofbywayoftradeinanyformofbindingorcoverotherthanthatinwhichitispublished,withoutthepriorwrittenconsentofEvaluateLtd.Copyright©2015EvaluateLtd.Allrightsreserved.3Copyright©2015EvaluateLtd.Allrightsreserved.AboutEvaluateMedTech®EvaluateMedTech®WorldPreview2015Foreword4Copyright©2015EvaluateLtd.Allrightsreserved.ThefourtheditionoftheEvaluateMedTech®WorldPreviewshowsthatthetotalvalueoftheglobalmedtechmarketisexpectedtoreach$477.5bnby2020,growingatanannualrateof4.1%overthecomingfiveyears(pages8-9).Theanalysisisbasedonin-depthforecastmodelsforthetop300globalmedtechcompaniesavailablewithinEvaluateMedTech®.TopofthetreeThelargestdevicemakerin2014wasJohnson&Johnsonwithmedtechsalesof$27.5bn,buttheindustryleaderin2020willbeMedtronicwithrevenuesof$34.9bn(pages12-13).Theswapofpositionsisduetothecompanies’divergentstrategies;J&JhasbeendivestingitsmedtechunitswhereasMedtronicisoneofthemostacquisitivecompaniesintheentiresector.Sincetheannouncementofits$49.9bnpurchaseofCovidien,thelargestdealintheindustry’shistory(pages29-30),Medtronichasannouncedafurther11acquisitionswithatotalvalueofaround$1.6bn.MergermaniaOthercompaniesthathavemoveduptherankingsthankstomegamergersincludeBectonDickinson,upsevenplacestonumberfivein2020followingitsacquisitionofCareFusion,andZimmerBiomet,alsoupsevenplacesto13thplacein2020,followingthemergerofthetwocompaniesthatmakeupitsname.Indeed,M&Aactivityhasdistinguishedthefirstsixmonthsof2015,withthetotalvalueofclosedmedtechmergerstopping$84bn,a166%riseonthetotalinH12014(pages29-30).However,EvaluateMedTech®foundthatthetotalnumberofdealsfellby18%to93inH12015.R&DAswellasbuyingtechnologiesinviatakeouts,Medtronicisspendingbigonin-houseresearch.ItisforecasttobethetopspenderonR&Din2020,withexpenditureof$2.5bnin2020(pages17-18)–notinsignificantconsideringthatthetotalspentworldwideonmedtechR&Disforecasttohit$29.5bnin2020(page16).However,intermsofpercentageofrevenues,diagnosticsspecialistbioMérieuxisexpectedtoinvestthemostintoR&Doutofthetop20companies,withanR&Dinvestmentrateof13.9%in2020.Oursalesforecastrepresentstheonlycurrentconsensusviewfromequityanalystsofthemedtechmarket.EvaluateMedTech®WorldPreview2015Foreword5Copyright©2015EvaluateLtd.Allrightsreserved.ApprovalsFortunately,theFDAislookingkindlyoninnovations,whetherproducedin-houseorboughtin.Thenumberoffirst-timePMAsandHDEsawardedbytheUSFDAincreased43%from2013toreach33in2014–andthisratehascontinuedinto2015(pages19-20).Duringthefirsteightmonthsof201533newPMAsandHDEshavebeengranted,comparedwith23inthesameperiodin2014–alsoanuptickof43%(pages21-23).EvaluateMedTech®WorldPreview2015Ahugewaveofconsolidationcrashedoverthemedtechindustryin2014andearly2015.Whilemegamergersarestilloccurring,withlucktheimmediatefuturewillbringasteadystreamofsmallertuck-inM&Adealstoo.IncombinationwithanincreaseinF